share_log

3 Stocks At 52-Week Lows That Could Bounce Big

3 Stocks At 52-Week Lows That Could Bounce Big

3只股票跌至52周低点,可能大幅反弹
Benzinga Real-time News ·  2021/04/01 05:15

One trading strategy an investor can profitably employ is to pick up an undervalued asset that has sold off due to factors that are extraneous or intrinsic to it. The strategy is premised on the belief that the asset can only go higher from this level.

投资者可以使用的一种有利可图的交易策略是买入被低估的资产,这些资产由于与其无关或内在的因素而被抛售。这一战略的前提是相信资产只能在这个水平上走得更高。

52-week Low As A Trading Signal: How do you zero in an undervalued stock? One approach would be to look around for a stock, or for that matter any asset, which is trading at or near its 52-week low. A 52-week low is the lowest level at which the stock has traded for the year.

作为交易信号的52周低点:你如何将被低估的股票归零?一种方法是四处寻找一只股票,或者就这一点而言,任何资产的交易价格都在或接近52周低点。52周低点是该股今年以来的最低交易水平。

Not all stocks that hit the lows for the year could turn out to be a profitable trade. Some of these stocks may have deteriorating fundamentals, and this could precipitate the weakness further. An astute investor, therefore, should also weigh in several other factors such as competitive positioning, market opportunity, regulatory environment, financial soundness, etc.

并不是所有触及年内低点的股票都可能成为有利可图的交易。其中一些股票的基本面可能正在恶化,这可能会进一步加剧疲软。因此,一个精明的投资者还应该权衡其他几个因素,如竞争定位、市场机会、监管环境、财务稳健等。

This approach is similar to "value buying" propounded by the likes of Warren Buffett. A value investor will focus on buying undervalued shares of companies, which have fairly robust fundamentals.

这种方法类似于沃伦·巴菲特(Warren Buffett)等人提出的“价值购买”。价值投资者将专注于购买被低估的公司股票,这些公司的基本面相当强劲。

Here are three stocks trading at or near their 52-week lows and promise strong upside potential.

以下是三只处于或接近52周低点的股票,有望实现强劲的上行潜力。

ADC Therapeutics SA (NYSE:ADCT)

ADC治疗公司(纽约证券交易所:ADCT)

This Swiss-based biopharma focuses on developing antibody-drug conjugates for treating patients with hematological malignancies and solid tumors.

这家总部设在瑞士的生物制药公司专注于开发抗体-药物结合物,用于治疗血液恶性肿瘤和实体肿瘤患者。

The company's shares hit a 52-week low of $21.51 in early March and have come off the level since then.

该公司股价在3月初触及52周低点21.51美元,此后已回落。

ADC reported in mid-March a wider loss for its fourth quarter and fiscal year 2020, amid ballooning operating expenses. The company had a cash balance of $439.2 million as of Dec. 31.

ADC在3月中旬报告称,由于运营费用不断膨胀,其第四季度和2020财年出现了更大范围的亏损。截至12月31日,该公司的现金余额为4.392亿美元。

Its lead candidate is loncastuximab tesirine, called Lonca, which has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell, mantle cell, and follicular lymphomas.

它的主要候选药物是LonCastuximab tesiine,称为LONCA,已在广泛的复发或难治性弥漫性大B细胞、套细胞和滤泡性淋巴瘤患者中显示出显著的单药临床活性。

ADC has several upcoming catalysts and if these play out positively, its stock could be in for a big reversal. The company's biologic license application for Lonca in relapsed or refractory DLBCL has a PDUFA action date of May 21. H.C. Wainwright ascribes a 75-95% probability of Lonca being approved.

ADC即将推出几个催化剂,如果这些催化剂发挥积极作用,其股价可能会出现大幅逆转。该公司对Lonca治疗复发或难治性DLBCL的生物许可证申请的PDUFA行动日期为5月21日。H.C.温赖特认为隆卡获得批准的可能性为75%-95%。

The average price target of analysts covering the biopharma's stock is $48.

研究这家生物制药公司股票的分析师的平均目标价为48美元。

Related Link: Why It's A Great Time To Be A Value Investor

相关链接:为什么现在是价值投资者的大好时机

BigCommerce Holdings, Inc. (NASDAQ:BIGC)

BigCommerce Holdings,Inc.(纳斯达克:BIGC)

BigCommerce is an open SaaS e-commerce platform for brands. The company offered its shares to the public in the middle of the COVID-19 pandemic. After a whopping listing gain of about 200%, the stock ran up to a high of $162.50 in the first month of listing.

BigCommerce是一个面向品牌的开放SaaS电商平台。该公司在新冠肺炎大流行期间向公众发行股票。在经历了约200%的巨大上市涨幅后,该股在上市的第一个月就涨到了162.50美元的高点。

On Tuesday, the stock hit a 52-week low of $50.59.

周二,该股触及52周低点50.59美元。

Piper Sandler analyst Brent Bracelin said in a note in early March that he sees multiple upside levers to growth estimates of 25%+ over the next one to three years. Incremental growth could come from new $1 billion, plus, gross merchandise value merchants, international expansion, accelerating partner-driven new merchants, new investments and further expansion into B2B.

派珀·桑德勒(Piper Sandler)分析师布伦特·布拉克林(Brent Bracelin)在3月初的一份报告中表示,他认为未来一到三年25%以上的增长预期存在多个上行杠杆。增量增长可能来自新的10亿美元,加上商品总价值商家、国际扩张、加速合作伙伴驱动的新商家、新投资和进一步向B2B扩张。

"As a cloud commerce pure-play with what we see as $1B+ revenue potential, we would be aggressive buyers of BIGC on the recent pull-back and view it as a core small-cap growth holding," Bracelin said in the note.

Bracelin在报告中表示:“作为一家纯粹的云商务公司,我们认为BIGC有超过10亿美元的营收潜力,我们将在最近的回调中积极买入BIGC,并将其视为核心的小盘股增长持股。”

Ganfeng Lithium Co., Ltd. (OTC:GNENF)

赣锋锂业股份有限公司(场外交易:GNENF)

Ganfeng Lithium is a China-based supplier of lithium, which is used in the batteries of EVs. It counts Tesla, Inc. (NASDAQ:TSLA) and Bayerische Motoren Werke Aktiengesellschaft (OTC:BMWYY) among its customers.

赣锋锂是一家总部位于中国的锂供应商,锂用于电动汽车的电池。它算数的特斯拉公司(纳斯达克:特拉斯)和巴伐利亚摩托伦维尔克阿克提恩格斯勒(场外交易:BMWYY)在其客户中。

Rising demand from the booming EV industry led to a strong financial performance by the company in fiscal year 2020. The industry is gradually shifting from a balanced supply and demand to a tight supply situation, the company said. This is validated by Romeo Power, Inc.'s (NASDAQ:RMO) warning that it won't be able to meet battery pack delivery commitments to customers in 2021 due to a shortage of batteries.

蓬勃发展的电动汽车行业不断增长的需求导致该公司在2020财年实现了强劲的财务表现。该公司表示,该行业正逐渐从供需平衡转向供应紧张局面。这一点通过以下方式进行验证罗密欧电力公司(Romeo Power,Inc.)(纳斯达克:RMO)警告称,由于电池短缺,该公司将无法在2021年实现向客户交付电池组的承诺。

Ganfeng Lithium stock, which is traded over the counter, hit a 52-week low of $11 on March 8 and is currently trading around $12.50.

在场外交易的赣锋锂业股票在3月8日触及52周低点11美元,目前交易价格在12.50美元左右。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发